Indivumed GmbH
Indivumed is a global oncology company and a unique resource for accelerating cancer research and advancing precision oncology. Driven by their mission to unveil the complex mechanisms of cancer, Indivumed combines the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics. Utilizing a global clinical network and using a standardized approach, Indivumed collects biospecimens and comprehensive clinical information of unparalleled depth and quality. Based on this data, the company offers specialized products and services, as well as development partnerships that support customers in obtaining novel insights, discovering biomarkers and targets, drug development, clinical trials, and much more.
Indivumed at a glance:
| Field of activity | Preclinical/Clinical Services, Bioinformatics, AI Analytics, Laboratory Service, and Biobank Products |
| Ownership Structure and Financing | Founder & Private Investors |
| Partners | Close partnerships with clinical institutions all over the world to collect biospecimens and clinical data. Establishment of the Oncology Alliance for Individualized Medicine (Onco AI-Med) to conduct cancer research. Establishment of the drug development company Ix Therapeutics. |
| Products/Services | • CRO Services • Biobank & Biobank Know-How • IHC Screening of Clinical Trial Samples • Early Oncology R&D Services • Drug Development Partnerships |
| Unique Selling Point | • Unique and highly standardized biospecimen collection process. • The world’s most comprehensive multi-omics cancer database. • AI platform combining disease models, analytical algorithms, and machine learning. |
| Membership in Networks/Associations | BIO Deutschland, Life Science Nord e.V., ESBB, EACR, AACR |
| Date of Incorporation/Number of employees | 2002 / 230 |
Contact
Founder and Chief Executive Officer Indivumed Group
| Adress | Falkenried 88, Bldg. D 20251 Hamburg |
| Telephone | +49 40 41 33 83-0 |
| info@indivumed.com | |
| Web Address | www.indivumed.com |
| Social Media | LinkedIn Twitter |
- „Ritter-RNA“ wird zum wichtigsten kleinen Biotech-Helden gewählt
- Gute Stimmung, aber der Blick in die Zukunft ist nicht ungetrübt
- What we need for a thriving bioeconomy in Germany
- Aufruf von BIO Deutschland: „Biotechnologie-Agenda jetzt“
- BIO Deutschland wählt neuen Vorstand
- Rückblick Deutsche Biotechnologietage (DBT) 2021
- AC immune meldet positive Daten beim tau-Alzheimer-Projekt...
- eHealth-Allianz: Digitalisierung des Gesundheitswesens
- "Ich sehe uns als Innovationstreiber" - Hamburger Indivumed im Porträt
- Deutsche Biotech: Rekordfinanzierung und hohe Erwartungen an die Politik
- „KI ist so alt wie die Informatik selbst“
- Wir müssen draußen bleiben!
- Corona-Tests für Deutschland: Diagnostik-Anbieter sehen sich gut aufgestellt
- EY-Biotechnologie-Report 2020: Translation wird immer wichtiger
- Interview mit Ulrike Hinrichs, BVK, und Dr. Viola Bronsema, BIO Deutschland
- Plattform Life Sciences: Die neue Ausgabe "Financing Life Sciences" ist erschienen
- To improve the financial ecosystem
- Warten auf große Taten
- Biotech-Branche vermeldet erneut gute Finanzierungszahlen
- Wettbewerb „Biophorie – Euphorie für die Biotechnologie“ startet